GlassScriptPhysician profile
Denise M Rivers
NPI 1932193471
$4,024.01
in general payments reported to CMS, 2019-2025
29 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $294 · 2021: $284 · 2022: $640 · 2023: $975 · 2024: $1,309 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453 · Education: $21.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.34 |
| Education | $21.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.25 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Mallinckrodt Hospital Products INC. | $413.75 | 2020-2024 | Terlivaz, Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $370.13 | 2022-2025 | |
| Vifor Pharma, INC. | $363.46 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $268.01 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $249.57 | 2019-2024 | Ultomiris |
| Travere Therapeutics, INC. | $224.28 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.21 | 2020-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $186.28 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $175.94 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $143.40 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $142.61 | 2022-2024 | Lupkynis |
| Daiichi Sankyo INC. | $96.28 | 2022-2024 | Injectafer |
| Ani Pharmaceuticals, INC. | $86.35 | 2022-2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $85.82 | 2020-2023 | Krystexxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $73.07 | 2019-2024 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $68.88 | 2019-2022 | |
| Kyowa Kirin, INC. | $66.66 | 2023-2024 | Crysvita |
| Alnylam Pharmaceuticals INC. | $65.19 | 2019-2023 | Amvuttra |
| Glaxosmithkline, LLC. | $57.12 | 2021 | |
| Baxter Healthcare | $44.51 | 2019-2023 | Renal - Acute |
| Lundbeck LLC | $39.17 | 2019 | |
| Ardelyx, INC. | $33.36 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $28.38 | 2019 | |
| Rockwell Medical, INC. | $23.81 | 2020 | |
| Lilly USA, LLC | $16.86 | 2025 | Jardiance |
| Shire North American Group INC | $16.66 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Rivers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.